The FDA on December 1, 2023, granted accelerated approval to JAYPIRCA® for adults with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. JAYPIRCA® is a product of Eli Lilly and Company.
Bottom Ad
Advertisement
Subscribe
